Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Autor: Oliveira, Mafalda *, Pominchuk, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Vladimirov, Vladimir, Zamagni, Claudio, Denys, Hannelore, Forget, Frédéric, Horvath, Zsolt, Nesterova, Alfiya, Ajimi, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin P O, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher J, Traugottova, Zuzana, van Zyl, Ruaan, Arkania, Ekaterine
Zdroj: In The Lancet Oncology November 2024 25(11):1424-1439
Databáze: ScienceDirect